| First Author | Ursini-Siegel J | Year | 2007 |
| Journal | Nat Rev Cancer | Volume | 7 |
| Issue | 5 | Pages | 389-97 |
| PubMed ID | 17446858 | Mgi Jnum | J:120946 |
| Mgi Id | MGI:3708411 | Doi | 10.1038/nrc2127 |
| Citation | Ursini-Siegel J, et al. (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7(5):389-97 |
| abstractText | One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease. |
